Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Nov 10, 2022 6:35pm
176 Views
Post# 35090036

RE:RE:New Paper from Dr. McFarland

RE:RE:New Paper from Dr. McFarlandYears of work before it gets to bedside.  But if it fall under our patent (this is an Os(II) molecule but is their subtilities that would not make it fall under our patent, this has to be verified), it could be part of the IP portfolio.  


ML stands for McFarland Laboratory.  

3. Results and Discussion

We have previously reported that the unformulated, free ML18J03 used in this study has EC50 values ranging from 7 × 10−4 μM to 0.0434 μM in SK-MEL-28 melanoma cells, following broadband visible light excitation, with considerable inter-assay variability due to its propensity to aggregate [10]. The liposomal and micellar formulations of ML18J03 from our previous study have EC50 values of 98.1 × 10−4 μM and 49.1 × 10−4 μM, respectively, in SK-MEL-28 cells following broadband visible light excitation. Using related cyclometalated Ru(II) complexes, we previously reported EC50 values ranging from 0.142 μM to 0.258 μM in SK-MEL-28 and HL60 cells following broadband visible light excitation [20]. Using [Os(phen)2(IP-nT)]Cl2 complexes related to ML18J03, with varying thiophene chain lengths (nT), we also reported EC50 values following broadband visible light excitation ranging from 1 μM to 3 μM for Os-nT = 0 to 2, and 0.153 μM to 18 × 10−6 μM for Os-3T and Os-4T, respectively [8]. However, the low water solubility and extensive aggregation can be significant limitations for these compounds. Our ruthenium-based photosensitizer (TLD1433) currently being evaluated in clinical trials exhibits an EC50 value of 1.9 × 10−4 μM in SK-MEL-28 [7]. Other clinically approved PSs, such as Verteporfin (Visudyne; Bausch + Lomb, Laval, Canada) and Porfimer Sodium (Photofrin; Pinnacle Biologics, Bannockburn, IL) exhibit EC50 values of 0.61–1.21 µM and 4.5 µM, respectively [21,22]. To put the PDT efficacy of Mic-ML18J03 into perspective, a comparison with other reported micelles previously used for PDT can be made. C225-conjugated chlorin e6-loaded polymeric micelles have exhibited an EC50 value of 0.173 μM in A431 cells [23]. Furthermore, Protoporphyrin IX-lipid micelles exhibited an EC50 value of 35.6 μM in HeLa cells [24]. A folate-mediated and pH-responsive chidamide-bound micelle system encapsulating the PS pyropheophorbide-a also exhibited an EC50 value of 0.062 μM in A2780 cells [25]. While direct comparisons of EC50 do not take into consideration the wavelength, fluence and irradiance of photoexcitation, it is still evident that ML18J03 is a highly potent PS that is active in hypoxia and in normoxia. Micellar formulation of ML18J03 also improves water solubility and offers a more robust PDT response with significantly lower inter-assay variability. As such, this study proceeds to explore the ability of micellar formulation to significantly enhance the in vivo luminescence imaging options for ML18J03.
<< Previous
Bullboard Posts
Next >>